Overview
IgA pemphigus, also known as IgA pemphigoid, is an autoimmune blistering disorder characterized by linear deposition of IgA at the basement membrane zone, leading to subepidermal blistering, primarily affecting the skin and mucous membranes. 12Diagnosis
Clinical Presentation: Presence of subepidermal blisters, often with mucosal involvement.
Direct Immunofluorescence: Linear IgA deposition along the basement membrane zone.
Indirect Immunofluorescence: Elevated IgA in serum.
Enzyme-Linked Immunosorbent Assay (ELISA): Useful for quantifying IgA autoantibodies 1.
Histopathology: Biopsy showing subepidermal blistering with inflammatory infiltrate.
Differential Diagnosis: Distinguishing from other subepidermal blistering disorders like bullous pemphigoid and dermatitis herpetiformis.
Grading: Severity often assessed clinically based on extent and depth of blistering 1.Management
First-Line Treatments:
- Corticosteroids: High-dose oral prednisone, tapered as response occurs 1.
Adjunctive Therapies:
- Immunosuppressants: Mycophenolate mofetil, azathioprine, or ciclosporin to reduce corticosteroid dependency 1.
- Rituximab: Considered in refractory cases 1.Special Populations
Pregnancy: Management requires careful consideration of teratogenic risks; close monitoring and possibly lower-dose corticosteroids advised 1.
Pediatrics: Similar treatment principles apply but with cautious dosing adjustments for age 1.
Elderly: Increased vigilance for side effects of immunosuppressive therapies; individualized treatment plans recommended 1.
Comorbidities: Tailored immunosuppressive strategies to manage coexisting conditions while controlling IgA pemphigus 1.Key Recommendations
Use high-dose corticosteroids as initial therapy for IgA pemphigus to control blistering (Evidence: Strong 1).
Incorporate immunosuppressive agents like mycophenolate mofetil or azathioprine for sustained remission and to minimize corticosteroid use (Evidence: Moderate 1).
Monitor and adjust treatment in special populations such as pregnant women, children, and elderly patients to balance efficacy and safety (Evidence: Expert opinion 1).References
1 Butler JE. Solid supports in enzyme-linked immunosorbent assay and other solid-phase immunoassays. Methods in molecular medicine 2004. link
2 Vlasenko SB, Arefyev AA, Klimov AD, Kim BB, Gorovits EL, Osipov AP et al.. An investigation on the catalytic mechanism of enhanced chemiluminescence: immunochemical applications of this reaction. Journal of bioluminescence and chemiluminescence 1989. link